RATIONALE: Increasing survival at extremely low gestational ages is associated with very high rates of bronchopulmonary dysplasia (BPD) but is rarely quantified. OBJECTIVES: To identify respiratory morbidity and risk factors in the EPICure cohort over the first 6 years of life. METHODS: 308 babies born at < or =25 weeks' gestation in 1995 were followed up at 30 months and 6 years of age. Respiratory outcome was evaluated using clinical assessment, parental questionnaire and peak expiratory flow (PEF) at 6 years. RESULTS: 74% of this population received supplemental oxygen at 36 weeks postmenstrual age and 36% were discharged with supplemental oxygen which continued for a median of 2.5 months (75th percentile: 8.5 months). 236 children were followed to 6 years. Respiratory symptoms and medication use were more prevalent at 30 months and 6 years in children with BPD compared to those without. Children without BPD (n = 56) were not significantly different from their classmates but had consistently higher prevalence of poor respiratory health. Symptoms, need for hospital admission and medication use declined between 30 months and 6 years. 200 index children completed three PEF measures; PEF was lower than in classmates (mean adjusted difference: 39 l/min (95% CI 30 to 47)) and was lowest in children discharged home with oxygen and in those with BPD. Gestational age, BPD and maternal smoking at home and in pregnancy were independent risk factors for symptoms, but BPD was the only independent associate of PEF. CONCLUSION: Extremely preterm children have a continuum of poor respiratory health over the first 6 years, which is exacerbated by smoking during pregnancy and in the home.
RATIONALE: Increasing survival at extremely low gestational ages is associated with very high rates of bronchopulmonary dysplasia (BPD) but is rarely quantified. OBJECTIVES: To identify respiratory morbidity and risk factors in the EPICure cohort over the first 6 years of life. METHODS: 308 babies born at < or =25 weeks' gestation in 1995 were followed up at 30 months and 6 years of age. Respiratory outcome was evaluated using clinical assessment, parental questionnaire and peak expiratory flow (PEF) at 6 years. RESULTS: 74% of this population received supplemental oxygen at 36 weeks postmenstrual age and 36% were discharged with supplemental oxygen which continued for a median of 2.5 months (75th percentile: 8.5 months). 236 children were followed to 6 years. Respiratory symptoms and medication use were more prevalent at 30 months and 6 years in children with BPD compared to those without. Children without BPD (n = 56) were not significantly different from their classmates but had consistently higher prevalence of poor respiratory health. Symptoms, need for hospital admission and medication use declined between 30 months and 6 years. 200 index children completed three PEF measures; PEF was lower than in classmates (mean adjusted difference: 39 l/min (95% CI 30 to 47)) and was lowest in children discharged home with oxygen and in those with BPD. Gestational age, BPD and maternal smoking at home and in pregnancy were independent risk factors for symptoms, but BPD was the only independent associate of PEF. CONCLUSION: Extremely preterm children have a continuum of poor respiratory health over the first 6 years, which is exacerbated by smoking during pregnancy and in the home.
Authors: Soumyaroop Bhattacharya; Diana Go; Daria L Krenitsky; Heidi L Huyck; Siva Kumar Solleti; Valerie A Lunger; Leon Metlay; Sorachai Srisuma; Susan E Wert; Thomas J Mariani; Gloria S Pryhuber Journal: Am J Respir Crit Care Med Date: 2012-06-21 Impact factor: 21.405
Authors: Anne Greenough; John Alexander; Jill Boorman; Philip A J Chetcuti; Ian Cliff; Warren Lenney; Colin Morgan; Nigel J Shaw; Karl P Sylvester; Jackie Turner Journal: Eur J Pediatr Date: 2011-01-12 Impact factor: 3.183
Authors: Jessica Y Islam; Roberta L Keller; Judy L Aschner; Tina V Hartert; Paul E Moore Journal: Am J Respir Crit Care Med Date: 2015-07-15 Impact factor: 21.405
Authors: Paul E Moore; Jason T Poston; Debra Boyer; Emily Barsky; Jonathan Gaffin; Kathleen B Boyne; Kristie R Ross; Laura Beth Mann Dosier; Timothy J Vece; Alicia M Casey; Sebastian K Welsh; J Wells Logan; Edward G Shepherd; Pelton A Phinzy; Howard B Panitch; Christina M Papantonakis; Eric D Austin; Amir B Orandi; Maleewan Kitcharoensakkul; Mark K Abe; Amjad Horani; Jordan S Rettig; Jessica Pittman Journal: Ann Am Thorac Soc Date: 2017-08
Authors: John R Hurst; Joanne Beckmann; Yanyan Ni; Charlotte E Bolton; Carmel M McEniery; John R Cockcroft; Neil Marlow Journal: Am J Respir Crit Care Med Date: 2020-08-01 Impact factor: 21.405
Authors: Joseph Fawke; Sooky Lum; Jane Kirkby; Enid Hennessy; Neil Marlow; Victoria Rowell; Sue Thomas; Janet Stocks Journal: Am J Respir Crit Care Med Date: 2010-04-08 Impact factor: 21.405
Authors: L Marcela Merchan; Hazem E Hassan; Michael L Terrin; Ken B Waites; David A Kaufman; Namasivayam Ambalavanan; Pamela Donohue; Susan J Dulkerian; Robert Schelonka; Laurence S Magder; Sagar Shukla; Natalie D Eddington; Rose M Viscardi Journal: Antimicrob Agents Chemother Date: 2014-11-10 Impact factor: 5.191
Authors: Nicole Deptula; Emily Royse; Matthew W Kemp; Yuichiro Miura; Suhas G Kallapur; Alan H Jobe; Noah H Hillman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-06-24 Impact factor: 5.464